United Therapeutics FDA Accepts Tyvaso sNDA for IPF
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., September 2, 2026 United Therapeutics Corporation announced that the U.S. Food...
idiopathic pulmonary fibrosis
Advertisement
Celea Therapeutics Advances Phase 3 Deupirfenidone Program in IPF
August 24, 2026 | Boston, Massachusetts, USA Celea Therapeutics announced that it will present new clinical development updates for...
Rein Therapeutics Gains FDA Fast Track for LTI-03 in IPF
Austin, Texas, August 20, 2026 Rein Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
Contineum Therapeutics Affirms Phase 2 Milestones and Cash Runway
SAN DIEGO, July 30, 2026 Contineum Therapeutics, Inc. reported its second-quarter 2026 financial results while reaffirming key clinical development...
MannKind Reports Positive Phase 1b INFLO-1 IPF Results
Danbury, Conn. & Westlake Village, Calif., July 29, 2026 MannKind Corporation announced positive topline results from its Phase 1b...
Advertisements
Rein Therapeutics Expands Phase 2 RENEW Trial Across Five Countries
Austin, Texas, USA | July 21, 2026 Rein Therapeutics announced that its Phase 2 RENEW clinical trial evaluating the...
Boehringer Reports Strong H1 2026 Sales
INGELHEIM, Germany, July 15, 2026 Boehringer Ingelheim reported strong financial and operational performance for the first half of 2026,...
Syndax Unveils SNDX-4321, Expands Pipeline
NEW YORK, July 14, 2026 Syndax Pharmaceuticals unveiled two new pipeline candidates during its 2026 R&D Event, expanding its...
Celea Doses First Patient in Phase 3 SURPASS-IPF Trial
BOSTON, July 13, 2026 Celea Therapeutics announced that the first patient has been dosed in the global Phase 3...
Insilico Begins Phase III Trial of AI-Designed IPF Therapy
CAMBRIDGE, Mass., July 7, 2026 Insilico Medicine has announced the initiation of its Phase III clinical trial evaluating Rentosertib,...
Advertisement
